¼¼°èÀÇ È¯ÀÚ µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå(-2030³â) : Áúȯ, Á¦Ç°, ÀÌ¿ë »ç·Ê, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ªº°
Patient Registry Software Market by Disease (Diabetes, Cancer, Rare, Asthma, Kidney), Product (Drugs, Device), Use Case (Population Health, Research), End User [(Profit: Pharma, Payer, Hospital), (Non-Profit: Govt)] & Region - Global Forecast to 2030
»óǰÄÚµå : 1780347
¸®¼­Ä¡»ç : MarketsandMarkets
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 381 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 6,896,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,650 £Ü 9,265,000
PDF (5-user License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,150 £Ü 11,355,000
PDF (Corporate License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÀÌ¿ë Àοø¿¡ Á¦ÇÑÀº ¾øÀ¸³ª, ±¹³»¿¡ ÀÖ´Â »ç¾÷À常 ÇØ´çµÇ¸ç, ÇØ¿Ü ÁöÁ¡ µîÀº Æ÷ÇÔµÇÁö ¾Ê½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 13,933,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. (100% ÀÚȸ»ç´Â µ¿ÀÏ ±â¾÷À¸·Î °£Áֵ˴ϴÙ.) Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ È¯ÀÚ µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå ±Ô¸ð´Â 2025³â 22¾ï 5,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2030³â¿¡´Â 36¾ï 1,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 9.8%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

ÀÇ·á ½Ã½ºÅÛÀº ÄɾîÀÇ ÁúÀ» Çâ»ó½ÃŰ°í ±ÔÁ¦ ¿ä±¸ »çÇ×À» ÃæÁ·Çϱâ À§ÇØ È¯ÀÚ µ¥ÀÌÅÍ ¼öÁý ¹× ºÐ¼®¿¡ Á¡Á¡ ´õ ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. °Ç°­ °ü¸®¸¦ Áö¿øÇÕ´Ï´Ù.ÀÌ Ç÷§ÆûÀº ÀǾàǰ Æò°¡ ¹× °¡Ä¡ ±â¹Ý °ü¸®¸¦ Áö¿øÇÏ´Â ½ÇÁ¦ ¼¼°è µ¥ÀÌÅ͸¦ âÃâÇÏ´Â µ¥ ÇʼöÀûÀÌ¸ç ±Ã±ØÀûÀ¸·Î ÀÇ·á ºñ¿ëÀ» ÁÙÀÌ°í ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿ªÇÒÀ»ÇÕ´Ï´Ù.

Á¶»ç ¹üÀ§
Á¶»ç ´ë»ó ¿¬µµ 2023-2030³â
±âÁØ ¿¬µµ 2024³â
¿¹Ãø ±â°£ 2025-2030³â
´ÜÀ§ ±Ý¾×(´Þ·¯)
ºÎ¹® Á¦Ç°, ÀÌ¿ë »ç·Ê, µî·Ï À¯Çü, µµÀÔ ¸ðµ¨ ¹× ÃÖÁ¾ »ç¿ëÀÚ
´ë»ó Áö¿ª ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Patient Registry Software Market-IMG1

ȯÀÚ Á÷Á¢ µî·Ï ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ȯÀÚ µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀº ȯÀÚ Á÷Á¢ µî·Ï°ú »çÀÌÆ® ±â¹Ý ¹× ÀÓ»ó µ¥ÀÌÅÍ µî·ÏÀ¸·Î ³ª´¹´Ï´Ù. ȯÀÚ Á÷Á¢ µî·Ï ½Ã½ºÅÛÀº ȯÀÚ Âü¿© Áõ°¡, µðÁöÅÐ ÇコÄÉ¾î µµ±¸(ePRO ¹× ¸ð¹ÙÀÏ ¾Û µî)ÀÇ Ã¤ÅÃ, ȯÀÚ ±â¹Ý ½Ç¼¼°è Áõ°Å¿¡ ´ëÇÑ ¼ö¿ä, ȯÀÚ º¸°í °á°ú¿¡ ÃÊÁ¡À» ¸ÂÃá ºÐ»êÇü ÀÓ»ó ½ÃÇèÀÇ È®»êÀ¸·Î ÀÎÇØ °¡Àå ³ôÀº ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °¡»ó Ç÷§ÆûÀº µ¥ÀÌÅÍ ¼öÁýÀ» °£¼ÒÈ­ÇÏ¿© ÀÇ·á Á¦°øÀÚÀÇ ºÎ´ãÀ» ÁÙÀ̰í Àå±âÀû ÃßÀû °ü¸® ¹× ´Ù¾çÇÑ È¯ÀÚ ¸ðÁýÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

2024³â¿¡´Â ÀÇ·á ¿¬±¸ ¹× ÀÓ»ó ¿¬±¸ ºÎ¹®ÀÌ ÀÌ¿ë »ç·Êº°·Î ȯÀÚ µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀÔ´Ï´Ù.

2024³â¿¡´Â ÀÇ·á ¿¬±¸ ¹× ÀÓ»ó ¿¬±¸ ºÎ¹®ÀÌ È¯ÀÚ µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀ» Áö¹èÇÒ °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº ÀÓ»ó ½ÃÇè ¹× ÀǾàǰ °³¹ß¿¡ ½ÇÁ¦ µ¥ÀÌÅÍ(RWD) ¹× ½ÇÁ¦ Áõ°Å(RWE)ÀÇ »ç¿ëÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Å©°Ô ÃËÁøµÉ °ÍÀÔ´Ï´Ù. ȯÀÚ µî·Ï ¼ÒÇÁÆ®¿þ¾î´Â ±¸Á¶È­µÇ°í Á¾´ÜÀûÀΠȯÀÚ µ¥ÀÌÅ͸¦ ĸóÇÏ¿© ¿¬±¸ÀÚ°¡ °á°ú¸¦ ºÐ¼®ÇÏ°í ¾ÈÀü¼ºÀ» ¸ð´ÏÅ͸µÇÏ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù. ¸ÂÃãÇü ÀǾàǰÀÇ ºÎ»ó°ú »ý¸í °úÇÐ ±â¾÷, Çмú ¼¾ÅÍ ¹× °øÁß º¸°Ç ±â°ü °£ÀÇ Çù·ÂÀÌ °­È­µÇ¸é¼­ °­·ÂÇÑ µî·Ï ÀÎÇÁ¶ó¿¡ ´ëÇÑ Çʿ伺ÀÌ ´õ¿í ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ºÐ»êÇü ÀÓ»ó ½ÃÇè ¹× ½ÃÆÇ ÈÄ °¨½Ã·Î ÀüȯµÇ´Â Ãß¼¼µµ ÀÌ ºÎ¹®ÀÇ ¼±µµÀû À§Ä¡¸¦ °­È­Çϰí ÀÖ½À´Ï´Ù.

2024³â¿¡ ºÏ¹Ì´Â ȯÀÚ µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

2024³â¿¡´Â °­·ÂÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©¿Í µðÁöÅÐ ÇコÄɾîÀÇ Á¶±â äÅÿ¡ ÈûÀÔ¾î ºÏ¹Ì°¡ ȯÀÚ µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. MRO Corp ¹× ImageTrend¿Í °°Àº ÁÖ¿ä ¾÷üµéÀº °æÀï°ú Çõ½ÅÀ» °­È­Çϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ HHSÀÇ µ¥ÀÌÅÍ Çö´ëÈ­ ¹× CDCÀÇ ¸¸¼º Áúȯ °¨½Ã¿¡ ´ëÇÑ ÁýÁß°ú °°Àº ¿¬¹æ Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê´Â µî·Ï Ç÷§Æû¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ƯÈ÷, 2025³â 2¿ù, Veradigm°ú HealthVerity´Â ½ÉÇ÷°ü ¹× ´ë»ç µ¥ÀÌÅ͸¦ HealthVerityÀÇ °³ÀÎ Á¤º¸ º¸È£ Áؼö Ç÷§Æû°ú ÅëÇÕÇϱâ À§ÇØ Á¦ÈÞ¸¦ ¸Î¾î ȯÀÚ ¿©Á¤¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ¿¬±¸¸¦ °¡´ÉÇÏ°Ô Çß½À´Ï´Ù. ¶ÇÇÑ, 2024³â 4¿ù, ESO Solutions´Â µ¥ÀÌÅÍ ±â¹ÝÀÇ ÀÀ±Þ ´ëÀÀÀ» °³¼±ÇÏ°í »óÈ£ ¿î¿ë¼º°ú ȯÀÚ Ä¡·á °á°ú¸¦ Çâ»ó½Ã۱â À§ÇØ Logis Solutions¸¦ ÀμöÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ȯÀÚ µî·Ï ¼ÒÇÁÆ®¿þ¾î Çõ½Å ¹× µ¥ÀÌÅÍ ÅëÇÕ ºÐ¾ß¿¡¼­ ºÏ¹ÌÀÇ ¸®´õ½ÊÀ» ´õ¿í °ø°íÈ÷ ÇÒ °ÍÀÔ´Ï´Ù.

º» º¸°í¼­¿¡¼­´Â ¼¼°èÀÇ È¯ÀÚ µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀåÀ» Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä, ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ °¢Á¾ ¿µÇâ¿äÀÎ ºÐ¼®, ±â¼ú ¹× ƯÇã µ¿Çâ, ¹ý±ÔÁ¦ ȯ°æ, »ç·Ê ¿¬±¸, ½ÃÀå ±Ô¸ð ÃßÀÌ¿Í ¿¹Ãø, °¢Á¾ ±¸ºÐ ¹× Áö¿ª ¹× ÁÖ¿ä ±¹°¡º° »ó¼¼ ºÐ¼®, °æÀï ±¸µµ, ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀ» Á¤¸®Çß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå Áß¿ä ÀλçÀÌÆ®

Á¦5Àå ½ÃÀå °³¿ä

Á¦6Àå ȯÀÚ µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : µî·Ï À¯Çüº°

Á¦7Àå ȯÀÚ µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : Á¦Ç°º°

Á¦8Àå ȯÀÚ µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : ÀÌ¿ë »ç·Êº°

Á¦9Àå ȯÀÚ µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : µµÀÔ ¸ðµ¨º°

Á¦10Àå ȯÀÚ µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦11Àå ȯÀÚ µî·Ï ¼ÒÇÁÆ®¿þ¾î ½ÃÀå : Áö¿ªº°

Á¦12Àå °æÀï ±¸µµ

Á¦13Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦14Àå ºÎ·Ï

HBR
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global patient registry software market is expected to reach USD 3.61 billion by 2030 from USD 2.25 billion in 2025, at a CAGR of 9.8%. Healthcare systems are increasingly focused on capturing and analyzing patient data to enhance care quality and meet regulatory requirements. Patient registry software collects disease, procedure, and population data, facilitating clinical research and population health management. These platforms are vital for generating real-world evidence to support drug assessments and value-based care, ultimately reducing healthcare costs and driving market growth.

Scope of the Report
Years Considered for the Study2023-2030
Base Year2024
Forecast Period2025-2030
Units ConsideredValue (USD billion)
SegmentsProduct, Use Case, Registry Type, Deployment Model, and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
Patient Registry Software Market - IMG1

"The direct-to-patient registries segment is expected to witness the highest growth during the forecast period."

The patient registry software market is divided into direct-to-patient and site-based/clinical data registries. Direct-to-patient registries are expected to register the highest CAGR due to increased patient engagement, adoption of digital health tools (like ePRO and mobile apps), demand for real-world evidence from patients, and the rise of decentralized clinical trials that focus on patient-reported outcomes. Virtual platforms simplify data collection, easing the burden on healthcare providers and allowing for better longitudinal follow-up and diverse patient recruitment.

"The medical research & clinical studies segment held the largest share of the patient registry software market, by use case, in 2024."

In 2024, the medical research & clinical studies segment dominated the patient registry software market. This growth is largely driven by the increasing use of real-world data (RWD) and real-world evidence (RWE) for clinical trials and drug development. Patient registry software captures structured and longitudinal patient data, helping researchers analyze outcomes and monitor safety. The rise of personalized medicine and collaborations among life science companies, academic centers, and public health agencies further enhances the need for robust registry infrastructure. The shift toward decentralized trials and post-marketing surveillance also reinforces this segment's leading position.

"North America accounted for the largest share of the patient registry software market in 2024."

In 2024, North America held the largest share of the patient registry software market, driven by strong regulatory frameworks and early digital health adoption. Key players like MRO Corp and ImageTrend enhance competition and innovation. Federal initiatives, such as the US HHS's data modernization and the CDC's focus on chronic disease surveillance, increase the demand for registry platforms. Notably, in February 2025, Veradigm and HealthVerity partnered to integrate cardiovascular and metabolic data with HealthVerity's privacy-compliant platform, enabling comprehensive research on patient journeys. Additionally, in April 2024, ESO Solutions acquired Logis Solutions to improve data-driven emergency response, enhancing interoperability and patient outcomes. These developments solidify North America's leadership in patient registry software innovation and data integration.

The breakdown of primary participants is listed below:

Key Players in the Patient Registry Software Market

The key players in the patient registry software market include IBM (US), IQVIA Holdings Inc. (US), Health Catalyst Inc. (US), Oracle (US), UnitedHealth Group (US), Conduent Inc. (US), Elekta (Sweden), Dassault Systemes (France), EvidentIQ (Dacima Software Inc.) (Germany), MRO (Figmd, Inc.) (US), ImageTrend, Inc. (US), Global Vision Technologies, Inc. (US), Syneos Health (US), Veradigm LLC (US), ESO (US), Ordinal Data, Inc. (US), NEC Corporation (NEC Software Solutions UK Limited) (Japan), Cedaron Medical (US), Fivos Health (US), and Across Health (US).

Research Coverage

The report analyzes the patient registry software market. Its objective is to estimate the market size and future growth potential of various segments, categorized by product, registry type, use case, deployment model, end user, and region. Additionally, the report includes a competitive analysis of the key players in this market, featuring their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will help both established companies and new or smaller firms assess the market's current state, enabling them to capture a larger market share. Organizations that purchase this report can utilize one or more of the strategies outlined below to enhance their market positions.

This report provides insights on:

TABLE OF CONTENTS

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

6 PATIENT REGISTRY SOFTWARE MARKET, BY REGISTRY TYPE

7 PATIENT REGISTRY SOFTWARE MARKET, BY PRODUCT

8 PATIENT REGISTRY SOFTWARE MARKET, BY USE CASE

9 PATIENT REGISTRY SOFTWARE MARKET, BY DEPLOYMENT

10 PATIENT REGISTRY SOFTWARE MARKET, BY END USER

11 PATIENT REGISTRY SOFTWARE MARKET, BY REGION

12 COMPETITIVE LANDSCAPE

13 COMPANY PROFILES

14 APPENDIX

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â